注目すべき主な治療法の開発領域
ドラッグイノベーションの状況は進化しており、多くの企業が治療領域におけるデリバリーやターゲティングの課題に対処するためのプラットフォームを開発しています。
詳細は以下の通りです。
- 細胞治療・遺伝子治療
- CRISPR
- AIと機械学習による創薬
- RNA
- 標的型がん治療薬
Annually since January 2013, the Clarivate expert team has analyzed and selected the Drugs to Watch. While the underlying process has remained the same, the technologies have evolved, and new tools, such as Drug Timelines & Success Rates, are now available to inform the analysis.
| Drug Name | Company | Therapy Area | Year |
| Aducanumab | Biogen Inc., Esai Co Ltd. | Neurology/psychiatric - Alzheimer’s disease | 2021 |
| Vericiguat | Bayer AG, Merck & Co. | Cardiovascular – heart failure | 2021 |
| Relugolix | ASKA Pharmaceutical Co. Ltd., Gedeon Richter, Myovant Sciences Ltd, Pfizer Inc., Takeda Pharmaceutical Co. Ltd. | Oncology - prostate cancer, Reproductive health - endometriosis & uterine fibroids | 2021 |
| Bimekizumab | UCB | Excessive immune response/autoimmunity - psoriasis | 2021 |
| Filgotinib (GLPG-0634) | Galapagos NV, Gilead Sciences Inc. | Excessive immune response/autoimmunity | 2020 |
| Inclisiran (ALN-PCSsc; ALN-60212; PCSK9si; Leqvio) | The Medicines Co. | Cardiovascular disease | 2020 |
| Lisocabtagene maraleucel (JCAR-017; Liso-cel) | Celgene Corporation | Oncology | 2020 |
| Ofatumumab (OMB-157; Kesimpta) | Novartis International AG | Neurology/psychiatric | 2020 |
| Ozanimod (RPC-1063; Zeposia) | Celgene Corporation | Neurology/psychiatric | 2020 |
| Rimegepant (BHV-3000; Nurtec) | Biohaven Pharmaceutical Holding Co. Ltd. | Neurology/psychiatric | 2020 |
| Sacituzumab govitecan (IMMU-132) | Immunomedics Inc., Medicine Inc. | Oncology | 2020 |
| Semaglutide (Rybelsus) | Novo Nordisk A/S | Endocrinology/metabolic disease | 2020 |
| Trastuzumab deruxtecan (DS-8201a; Enhertu) | AstraZeneca plc, Daiichi Sankyo Co. Ltd. | Oncology | 2020 |
| Vadadustat | Akebia Therapeutics Inc., Mitsubishi Tanabe Pharma America Inc., Otsuka Pharmaceutical | Chronic disease complication | 2020 |
| Valoctocogene roxaparvovec (BMN-270; Valrox) | Biomarin Pharmaceutical Inc. | Genetic disorder | 2020 |
| Betibeglogene darolentivec (LentiGlobin) | Bluebird Bio Inc. | Genetic disorder | 2019 |
| Onasemnogene abeparvovec (AVXS-101; Zolgensma) | AveXis | Genetic disorder | 2019 |
| Palforzia (AR101; Aerumab) | Aimmune Therapeutics | Excessive immune response/autoimmunity | 2019 |
| Ravulizumab (ALXN-1210; Ultomiris) | Alexion Pharmaceuticals Inc. | Excessive immune response/autoimmunity, Genetic disorder | 2019 |
| Risankizumab (BI-655066; ABBV-066; Skyrizi) | AbbVie Inc., Boehringer Ingelheim | Excessive immune response/autoimmunity | 2019 |
| Roxadustat (FG-4592; AZD-9941; ASP-1517; Ai Rui Zhuo) | Astellas Pharma Inc., AstraZeneca plc, FibroGen | Chronic disease complication | 2019 |
| Upadacitinib (ABT-494; Rinvoq) | AbbVie Inc. | Excessive immune response/autoimmunity | 2019 |
| Apalutamide (Erleada) | Johnson & Johnson | Oncology | 2018 |
| Buprenorphine (Sublocade) | Indivior plc | Addiction | 2018 |
| Cannabidiol (Epidiolex) | GW Pharmaceuticals plc | Neurology/psychiatric | 2018 |
| Elagolix (Orilissa) | AbbVie Inc. | Reproductive health | 2018 |
| Emicizumab (Hemlibra) | Chugai, Roche | Hematology | 2018 |
| Erenumab (Aimovig) | Amgen, Novartis International AG | Neurology/psychiatric | 2018 |
| Ertugliflozin (Steglatro) | Merck & Co., Pfizer Inc. | Endocrinology/metabolic disease | 2018 |
| Lanadelumab (Takhzyro) | Shire | Genetic disorder | 2018 |
| Patisiran (Onpattro) | Alnylam Pharmaceuticals Inc., Sanofi Genzyme | Genetic disorder | 2018 |
| Shingrix vaccine | GlaxoSmithKline plc | Infectious disease | 2018 |
| Tenofovir alafenamide plus emtricitabine plus bictegravir (Biktarvy) | Gilead Sciences Inc. | Infectious disease | 2018 |
| Avelumab (Bavencio) | Merck Serono, Pfizer Inc. | Oncology | 2017 |
| Axicabtagene ciloleucel (KTE-C19; Yescarta) | Kite Pharma | Oncology | 2017 |
| Baricitinib (Olumiant) | Eli Lilly and Co., Incyte Corp. | Excessive immune response/autoimmunity | 2017 |
| Dupilumab (Dupixent) | Regeneron Pharmaceuticals Inc., Sanofi SA | Excessive immune response/autoimmunity | 2017 |
| Durvalumab (Imfinzi) | AstraZeneca plc | Oncology | 2017 |
| Niraparib (Zejula) | Tesaro | Oncology | 2017 |
| Ocrelizumab (Ocrevus) | Roche | Neurology/psychiatric | 2017 |
| Ribociclib (LEE-011; Kisqali) | Novartis International AG | Oncology | 2017 |
| Semaglutide (Ozempic) | Novo Nordisk A/S | Endocrinology/metabolic disease | 2017 |
| Emtricitabine plus tenofovir alafenamide (Descovy) | Gilead Sciences Inc., Japan Tobacco | Infectious disease | 2016 |
| Grazoprevir plus elbasvir (MK-5172A) | Merck & Co. | Infectious disease | 2016 |
ドラッグイノベーションの状況は進化しており、多くの企業が治療領域におけるデリバリーやターゲティングの課題に対処するためのプラットフォームを開発しています。
詳細は以下の通りです。
